GlassScriptPhysician profile
Charles B Evans
NPI 1992727143
$3,599.35
in general payments reported to CMS, 2019-2025
29 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $246 · 2021: $874 · 2022: $661 · 2023: $467 · 2024: $626 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,411.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.25 | 2019-2025 | Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $259.28 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $187.54 | 2021-2024 | Zeposia |
| Pfizer INC. | $163.83 | 2019-2025 | |
| Janssen Biotech, INC. | $157.04 | 2020-2025 | Simponi, Simponi Aria, Stelara |
| Medtronic USA, INC. | $121.83 | 2020 | |
| Nestle Healthcare Nutrition INC. | $118.65 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $114.14 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $111.92 | 2022-2025 | Suflave, Sutab |
| Allergan, INC. | $86.28 | 2019 | |
| Gilead Sciences, INC. | $78.66 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $69.77 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $62.00 | 2022-2024 | |
| Enterra Medical, INC. | $52.85 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $39.55 | 2023 | Captivator II, Compliance Endokit |
| Genzyme Corporation | $35.33 | 2025 | |
| Aimmune Therapeutics, INC. | $31.47 | 2025 | Zenpep, Vowst |
| Ardelyx, INC. | $31.32 | 2024 | Ibsrela |
| Echosens North America, INC. | $28.57 | 2021-2022 | |
| Novo Nordisk INC | $23.23 | 2025 | |
| Redhill Biopharma INC. | $22.24 | 2022 | |
| Coloplast Corp | $18.69 | 2022 | |
| Fresenius Kabi USA, LLC | $16.70 | 2024 | Idacio |
| Ipsen Biopharmaceuticals, INC | $15.87 | 2025 | Iqirvo |
| Lilly USA, LLC | $14.37 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $14.16 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $12.72 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.